Areas of good practice
OPAT / ambulatory antimicrobial pathway completed where indicated.
100%
Priority gaps
Critical care escalation completed where indicated. (target ≥ 90%)
33.3%
GP / community handover of the antimicrobial plan documented where relevant. (target ≥ 85%)
41.7%
IV-to-oral switch considered where clinically appropriate. (target ≥ 85%)
45%
Antibiotic regimen adjusted per culture / sensitivity where relevant. (target ≥ 85%)
46.7%
Patient information / advice on antibiotics documented where relevant. (target ≥ 75%)
50%
Review completed within the 48–72 hour window. (target ≥ 90%)
56.7%
Source control considered and documented where relevant. (target ≥ 85%)
58.3%
Microbiology / laboratory results reviewed and acted on. (target ≥ 90%)
60%
CARES decision (Continue / Amend / Refer / Escalate / Stop / Switch) documented at review. (target ≥ 90%)
63.3%
Discharge summary documents the antibiotic course, indication and stop date. (target ≥ 90%)
65%
Sepsis pathway followed where clinically applicable. (target ≥ 95%)
68.3%
Microbiology / infection specialist advice sought where required by policy. (target ≥ 90%)
68.4%
Duration or planned stop / review date documented. (target ≥ 90%)
70%
Cultures / relevant samples obtained before first antibiotic dose where clinically appropriate. (target ≥ 85%)
70%
Antibiotic review completed at 48–72 hours from first dose. (target ≥ 90%)
71.7%
Dose appropriate for renal / hepatic function and weight. (target ≥ 90%)
73.3%
Clinical response to antibiotic therapy documented. (target ≥ 85%)
73.3%
Monitoring plan (bloods, response, side effects) documented. (target ≥ 85%)
80%
Empirical antibiotic choice in line with local antimicrobial guideline. (target ≥ 90%)
81.7%
Allergy status documented on the prescription. (target ≥ 95%)
88.3%
Indication for antibiotic documented on the prescription. (target ≥ 95%)
90%
User commentary
Editable interpretation for reports and governance meetings.
Governance & safety implications
Any immediate antibiotic review, empirical guideline concordance, obstruction, sepsis, contrast or medication safety concern identified during this audit must be escalated through local clinical, renal, pharmacy, critical care and governance pathways. This tool does not replace local escalation processes.